Herceptin

(Trastuzumab)

ApprovedMonoclonal antibody

Trastuzumab is used to treat certain types of breast cancer and stomach cancer that have a specific protein called HER2 on their surface. It works by targeting and attacking cancer cells that have this protein, helping to slow or stop their growth.[2] Herceptin is currently approved and in use across 91 indications[4].[1]

Herceptin is one of 1063 monoclonal antibody programs targeting Colorectal Cancer. It is currently in Approved.

Indications

954

Total Trials

Active Trials

1,062

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Colorectal CancerCompleted

Lung CancerWithdrawn

Endometrial CancerCompleted

Metastatic Colorectal CancerRecruiting

Metastatic Breast CancerActive, not recruiting

ImmunotherapyUnknown status

Solid TumorsTerminated

Breast Cancer With Brain MetastasisRecruiting

CardiotoxicityActive, not recruiting

Invasive Breast CancerRecruiting

Colorectal CancerPhase 2

Completed

Lung CancerPhase 2

Withdrawn

Endometrial CancerPhase 2

Completed

Metastatic Colorectal CancerPhase 2

Recruiting

Metastatic Breast CancerPhase 3

Active, not recruiting

ImmunotherapyPhase 2

Unknown status

Solid TumorsPhase 2

Terminated

Breast Cancer With Brain MetastasisPhase 2

Recruiting

CardiotoxicityPreclinical

Active, not recruiting

Invasive Breast CancerPhase 2

Recruiting

Showing 10 of 91 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Herceptin

Adenocard

2 3

Lexiscan

Astellas

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

Spravato

WWim Janssens

Preclinical

2 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Cancer

NCT05159245

Phase 2Recruiting

Breast Cancer

NCT04481932

Not yet recruiting

Breast Cancer

NCT06537674

Phase 2Recruiting

Neoadjuvant Treatment

NCT07108127

Phase 2Recruiting

Breast Cancer

NCT04553770

Phase 1/2Recruiting

Gastric Cancer

NCT05640830

Clinical

Trials by Indication[1]

Breast Cancer125 trials

Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer

Withdrawn·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT00054470

Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00006381

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 3·NCT07377643·540 enrolled

Show 122 more trials

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Terminated·KKadmon Corporation, LLC·Phase 1/2·NCT02154529·17 enrolled

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Completed· Pfizer logo

Pfizer·Phase 1·NCT01969643·290 enrolled

Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer

Completed·AAnglo Celtic Cooperative Oncology Group·Phase 3·NCT00639366·390 enrolled

Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

Recruiting·FFujian Medical University Union Hospital·Phase 2·NCT05292742·206 enrolled

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

Not yet recruiting·FFudan University·Phase 3·NCT05841381·876 enrolled

Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 3·NCT00288002·1,500 enrolled

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

Terminated· Novartis logo

Novartis·Phase 1/2·NCT01132664·72 enrolled

A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

Completed· Roche logo

Roche·Phase 1·NCT02738970·88 enrolled

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01827163·20 enrolled

A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

Completed· Pfizer logo

Pfizer·Phase 3·NCT02187744·226 enrolled

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

Terminated· Novartis logo

Novartis·Phase 2·NCT02213042·42 enrolled

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 1/2·NCT00934856·98 enrolled

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Recruiting·HHenan Cancer Hospital·Phase 3·NCT07057427·812 enrolled

Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer

Unknown status·FFudan University·Phase 2·NCT01170143·60 enrolled

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano··NCT07030569·500 enrolled

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

Completed·—·Phase 2·NCT02789657·32 enrolled

Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases

Completed·MMedical University of Vienna·Phase 2·NCT04752059·15 enrolled

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03493854·500 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Withdrawn·—·Phase 1/2·NCT00006123

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

Not yet recruiting·Xxuexin he·Phase 2·NCT04158856·60 enrolled

A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT04539938·70 enrolled

Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer

Unknown status·HHebei Medical University Fourth Hospital··NCT03728829·100 enrolled

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

Terminated·UUniversity of Southern California·Phase 2·NCT01873833·10 enrolled

Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

Terminated· Incyte logo

Incyte·Phase 1/2·NCT01254136·20 enrolled

Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT04997798·30 enrolled

Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer

Completed·VVejle Hospital·Phase 2·NCT02909751·80 enrolled

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo··NCT06210776·800 enrolled

DP303c in Patients With HER2-positive Advanced Breast Cancer

Not yet recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT05901935·420 enrolled

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT06313086·442 enrolled

Basket Study for Oligo-metastatic Breast Cancer

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT05982678·72 enrolled

A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

No longer available· Roche logo

Roche··NCT01120561

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 2·NCT06832202·50 enrolled

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

Completed· Roche logo

Roche·Phase 3·NCT01419197·602 enrolled

Immunotherapy Vaccine and Herceptin in Breast Cancer

Completed·CCancer Insight, LLC·Phase 1·NCT03014076·30 enrolled

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

Completed· Daiichi Sankyo logo

Daiichi Sankyo··NCT05458401·256 enrolled

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT00509769·112 enrolled

Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy

Terminated·FFundacio Clinic Barcelona·Phase 2·NCT04578106·5 enrolled

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06125834·36 enrolled

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Completed·UUniversity of Washington·Phase 1/2·NCT00331552·30 enrolled

A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191373·66 enrolled

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Withdrawn·—·Phase 2·NCT04351230

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

Active, not recruiting·CCancer Trials Ireland·Phase 2·NCT05710666·11 enrolled

Brain Metastasis in Breast Cancer Patients

Completed· GSK logo

GSK··NCT01077648·1 enrolled

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University··NCT07358182·300 enrolled

Trastuzumab Deruxtecan in Advanced Breast Cancer

Recruiting·WWenjin Yin··NCT07180264·118 enrolled

Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting·MMedSIR·Phase 2·NCT04733118·393 enrolled

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT00068757·23 enrolled

Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer

Unknown status·FFudan University··NCT05594082·150 enrolled

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Completed·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT00033514·27 enrolled

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

Completed· Roche logo

Roche··NCT05945927·178 enrolled

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06409390·15 enrolled

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT04553770·88 enrolled

T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Completed·MMedSIR·Phase 1·NCT02562378·15 enrolled

A Study of Surgery and Radiotherapy in People With Breast Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07053085·162 enrolled

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT05760612·300 enrolled

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06102824·252 enrolled

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 1/2·NCT00951665·107 enrolled

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Completed· Roche logo

Roche·Phase 1/2·NCT00875979·67 enrolled

Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab

Unknown status·PPeking University Cancer Hospital & Institute··NCT05188495·60 enrolled

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 3·NCT07047365·416 enrolled

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

Terminated· AstraZeneca logo

AstraZeneca··NCT06231693·2 enrolled

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT00829166·991 enrolled

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT07416253·68 enrolled

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy

Completed· Roche logo

Roche·Phase 2·NCT02924883·202 enrolled

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03084939·351 enrolled

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Completed·NNYU Langone Health·Phase 2·NCT03742986·8 enrolled

Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

Unknown status·KKorean Cancer Study Group·Phase 2·NCT03698383·15 enrolled

Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07037199·45 enrolled

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Completed·IInstitut Curie·Phase 2·NCT01975142·155 enrolled

Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer

Active, not recruiting·CCentre Leon Berard·Phase 2·NCT03571633·90 enrolled

Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer

Terminated·HHoosier Cancer Research Network·Phase 2·NCT00216073·11 enrolled

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT06846437·228 enrolled

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 3·NCT07008976·246 enrolled

Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

Terminated·UUniversity of Miami·Phase 1/2·NCT02658084·2 enrolled

A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Terminated· Roche logo

Roche·Phase 1/2·NCT04298918·1 enrolled

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

Not yet recruiting·—·Phase 2·NCT07299890·90 enrolled

Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer

Unknown status·AAzienda Ospedaliera Ordine Mauriziano di Torino·Phase 2·NCT00842998·120 enrolled

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases

Active, not recruiting·MMedSIR·Phase 2·NCT06048718·28 enrolled

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Unknown status·CConsorzio Oncotech··NCT05754502·300 enrolled

Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT03153163·11 enrolled

Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer

Withdrawn·JJenny C. Chang, MD·Phase 2·NCT02725541

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT04538742·245 enrolled

Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

Active, not recruiting·TThomas Hatschek·Phase 2/3·NCT02568839·202 enrolled

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT04024462·200 enrolled

National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]

Completed·CComprehensive Support Project for Oncology Research·Phase 3·NCT01104935·275 enrolled

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

Unknown status·NN.N. Petrov National Medical Research Center of Oncology·N/A·NCT06299852·58 enrolled

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Recruiting·GGerman Cancer Research Center·Phase 2·NCT05332561·240 enrolled

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Not yet recruiting·—·Phase 1/2·NCT07198724·65 enrolled

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Completed· Roche logo

Roche·Phase 2·NCT00943670·51 enrolled

Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients

Unknown status·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT03144947·65 enrolled

Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery

Completed·UUniversity of Washington·Phase 1·NCT01816035·13 enrolled

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT05577442·52 enrolled

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

Withdrawn·DDanish Breast Cancer Cooperative Group·Phase 3·NCT06585969

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT05020964·68 enrolled

Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer

Not yet recruiting·JJiangsu Famous Medical Technology Co., Ltd.··NCT06537674·100 enrolled

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Completed· Roche logo

Roche·Phase 1·NCT01513083·28 enrolled

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns

Recruiting·SSun Yat-sen University··NCT06551220·800 enrolled

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Unknown status·FFudan University·Phase 3·NCT05346861·240 enrolled

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Recruiting·FFudan University·Phase 1·NCT06331169·42 enrolled

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

Recruiting·PPeking University·Phase 2·NCT04481932·104 enrolled

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT03674112·160 enrolled

Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy

Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT05560308·50 enrolled

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Recruiting·UUniversity of Chicago·Phase 2·NCT06348134·74 enrolled

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04494425·866 enrolled

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Recruiting·MMedSIR·Phase 2·NCT06172127·165 enrolled

Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06797622·50 enrolled

A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

Completed· Roche logo

Roche·Phase 1·NCT00932373·54 enrolled

Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

Completed·SSwiss Cancer Institute·Phase 2·NCT00238290·13 enrolled

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT05415215·346 enrolled

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

Active, not recruiting·WWest German Study Group·Phase 2·NCT05704829·402 enrolled

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT04457596·1,056 enrolled

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Terminated·CCancer Trials Ireland·Phase 1·NCT04042051·2 enrolled

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Unknown status·SShanghai Miracogen Inc.·Phase 2/3·NCT04924699·350 enrolled

A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer

Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 2·NCT01367028·100 enrolled

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT06328387·120 enrolled

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00036868·90 enrolled

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT05950945·250 enrolled

Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT07368543·216 enrolled

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Terminated· Roche logo

Roche·Phase 3·NCT04740918·96 enrolled

Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer

Terminated· Novartis logo

Novartis·Phase 4·NCT00171847·93 enrolled

A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer

Not yet recruiting·HHuihua Xiong·Phase 2·NCT06362096·72 enrolled

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

Completed· Roche logo

Roche·Phase 4·NCT02658734·70 enrolled

Gastric Cancer9 trials

NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer

Unknown status·NNational University Hospital, Singapore·Phase 1/2·NCT02030561·29 enrolled

A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Completed·NNational Cancer Centre, Singapore·Phase 2·NCT01736410·30 enrolled

Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer

Unknown status·XXuzhou Medical University·Phase 1/2·NCT02805829·20 enrolled

Show 6 more trials

Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)

Unknown status·YYonsei University·Phase 1/2·NCT04888663·50 enrolled

A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT01228045·30 enrolled

A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer

Completed·PPeking University·Phase 2·NCT01364493·51 enrolled

A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Terminated· Roche logo

Roche·Phase 2/3·NCT01641939·415 enrolled

Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

Recruiting·KKangbuk Samsung Hospital·Phase 1/2·NCT05640830·47 enrolled

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)

Terminated· Roche logo

Roche·Phase 2·NCT01702558·182 enrolled

Non-Small Cell Lung Cancer5 trials

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Active, not recruiting·EEnliven Therapeutics·Phase 1·NCT05650879·198 enrolled

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT04644237·152 enrolled

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT04042701·115 enrolled

Show 2 more trials

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 2·NCT02289833·49 enrolled

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Terminated· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT03505710·181 enrolled

Metastatic Colorectal Cancer4 trials

Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07059338·34 enrolled

Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer

Unknown status·FFondazione del Piemonte per l'Oncologia·Phase 2·NCT03225937·54 enrolled

Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.

Unknown status·FFondazione del Piemonte per l'Oncologia·Phase 2·NCT03418558·13 enrolled

Show 1 more trial

Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT07407465·42 enrolled

Adenocarcinoma3 trials

Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma

Recruiting·FFudan University··NCT07389876·250 enrolled

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT04704934·490 enrolled

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04989816·95 enrolled

44 more indications

Trial3 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03297606·720 enrolled

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Patients With Advanced Solid Tumors2 trials

BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00022529·28 enrolled

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Recruiting·GGI Innovation, Inc.·Phase 1/2·NCT05824975·358 enrolled

Solid Tumors2 trials

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Recruiting·EEisbach Bio GmbH·Phase 1/2·NCT06525298·144 enrolled

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT04639219·102 enrolled

Neoadjuvant Treatment2 trials

Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07108127·24 enrolled

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT07047755·48 enrolled

Treatment2 trials

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

Completed·MMedSIR·Phase 2·NCT04420598·41 enrolled

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04439110·38 enrolled

Gastroesophageal Junction Adenocarcinoma2 trials

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Recruiting·NNational Cancer Center Hospital East·Phase 2·NCT05034887·64 enrolled

A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting·AAurigene Discovery Technologies Limited·Phase 1/2·NCT07040059·18 enrolled

Growth2 trials

A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors

Completed· Roche logo

Roche·Phase 2·NCT02999672·20 enrolled

microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University··NCT02656589·300 enrolled

Cancer of the Pancreas1 trial

Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas

Unknown status·—·Phase 2·NCT00003797·41 enrolled

Metastatic Cancer1 trial

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00004856·40 enrolled

Ductal Carcinoma in Situ1 trial

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00769379·2,014 enrolled

Esophageal Cancer1 trial

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Recruiting·UUniversity of Southampton·Phase 2·NCT05965479·25 enrolled

Paclitaxel1 trial

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Completed·—·Phase 2·NCT01853748·512 enrolled

Immunotherapy1 trial

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02345772·4 enrolled

Biliary Tract Cancer1 trial

First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)

Recruiting·YYonsei University·Phase 1/2·NCT05749900·44 enrolled

Adjuvant Treatment1 trial

A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse

Recruiting·PProf. Wolfgang Janni·Phase 3·NCT06643585·180 enrolled

Newly Diagnosed1 trial

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

Not yet recruiting·UUniversity of Chicago·Phase 2·NCT07126561·43 enrolled

Cancer1 trial

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Recruiting·HHelsinki University Central Hospital·Phase 2·NCT05159245·250 enrolled

Metastatic Prostate Cancer1 trial

Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

Completed·—·Phase 2·NCT00005857

Clinical Trial1 trial

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting·UUlrik Lassen·Phase 2·NCT04341181·300 enrolled

Gallbladder Cancer1 trial

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00478140·4 enrolled

Phase II1 trial

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03334617·528 enrolled

Breast Ductal Carcinoma in Situ1 trial

Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study

Enrolling by invitation·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06843681·54 enrolled

Endometrial Cancer1 trial

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting·AAlliance Foundation Trials, LLC.·Phase 1/2·NCT04486352·148 enrolled

Gastric Adenocarcinoma1 trial

Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 1/2·NCT06731803·36 enrolled

Neoadjuvant1 trial

De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

Terminated·JJules Bordet Institute·Phase 2·NCT04675827·139 enrolled

Brain Cancer1 trial

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06058988·30 enrolled

Locally Advanced1 trial

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab

Terminated·SSpanish Breast Cancer Research Group·Phase 2·NCT05744375·2 enrolled

Urothelial Carcinoma1 trial

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

Recruiting·SSun Yat-sen University·Phase 2·NCT07241793·96 enrolled

Real-world Study1 trial

A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors

Active, not recruiting·LLixiaoling··NCT07387874·30 enrolled

Urothelial Cancer1 trial

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT03523572·86 enrolled

EGFR Mutation1 trial

T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC

Terminated·TThe Netherlands Cancer Institute·Phase 2·NCT03784599·28 enrolled

Tics1 trial

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

Completed· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT05765357·89 enrolled

First-line Treatment1 trial

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Not yet recruiting·FFudan University·Phase 2·NCT05953168·69 enrolled

Advanced Solid Tumors1 trial

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed· Roche logo

Roche·Phase 2·NCT04632992·252 enrolled

Lung Cancer1 trial

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases

Enrolling by invitation·YYonsei University·Phase 2·NCT06250777·27 enrolled

Resistance1 trial

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Active, not recruiting·UUniversity College, London·Phase 2·NCT02314481·50 enrolled

Capecitabine1 trial

A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

Unknown status·—·Phase 2·NCT04309578·28 enrolled

HER2-Positive Solid Tumor1 trial

Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor

Unknown status·JJin-Hee Ahn·Phase 2·NCT04215159·42 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Trastuzumab BS

Completed· Pfizer logo

Pfizer··NCT04181333·8 enrolled

Advanced Cancer1 trial

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04294628·62 enrolled

Refractory to Standard Therapies1 trial

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

Recruiting·SSheng Zhang·Phase 2·NCT07309770·90 enrolled

Gastroesophageal Junction1 trial

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Active, not recruiting·—·Phase 2·NCT05480384·1 enrolled

Chemotherapy1 trial

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Terminated·UUniversity of Maryland, Baltimore·Phase 2·NCT02000596·2 enrolled

Unspecified3 trials

NSABP Biospecimen Discovery Project

Unknown status·NNSABP Foundation Inc··NCT01850628·50 enrolled

The Synergism Or Long Duration (SOLD) Study

Completed·FFinnish Breast Cancer Group·Phase 3·NCT00593697·2,168 enrolled

Scalp Cooling in MBC

Recruiting·—·Phase 2·NCT04986579·120 enrolled

Regulatory

FDA Approval Timeline[5]

Sep 25, 1998

Herceptin

BLA 103792

Sep 25, 1998

HERCEPTIN

BLA BLA103792

Dec 14, 2018

HERZUMA

BLA BLA761091

Jan 18, 2019

ONTRUZANT

BLA BLA761100

Sources

References

[1]
ClinicalTrials.gov — 954 trial records for Trastuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Herceptin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Trastuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Trastuzumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA761100). U.S. Food & Drug Administration.
[6]
PubMed — 3 publications indexed for Trastuzumab. U.S. National Library of Medicine.
[7]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: HER2 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche

Key Publications[6]

Subcutaneous Trastuzumab in HER2-Positive Gastric Cancer: Phase 3 Results

Lancet OncolFeb 27, 2023DOI: 10.1016/S1470-2045(23)00025-1

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: DESTINY-Breast04

N Engl J MedFeb 3, 2022DOI: 10.1056/NEJMoa2115022

Trastuzumab Plus Pertuzumab in Early HER2-Positive Breast Cancer

N Engl J MedMay 24, 2021DOI: 10.1056/NEJMoa2101671

Herceptin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Breast Cancer125 trials

Gastric Cancer9 trials

Non-Small Cell Lung Cancer5 trials

Metastatic Colorectal Cancer4 trials

Adenocarcinoma3 trials

Trial3 trials

Patients With Advanced Solid Tumors2 trials

Solid Tumors2 trials

Neoadjuvant Treatment2 trials

Treatment2 trials

Gastroesophageal Junction Adenocarcinoma2 trials

Growth2 trials

Cancer of the Pancreas1 trial

Metastatic Cancer1 trial

Ductal Carcinoma in Situ1 trial

Esophageal Cancer1 trial

Paclitaxel1 trial

Immunotherapy1 trial

Biliary Tract Cancer1 trial

Adjuvant Treatment1 trial

Newly Diagnosed1 trial

Cancer1 trial

Metastatic Prostate Cancer1 trial

Clinical Trial1 trial

Gallbladder Cancer1 trial

Phase II1 trial

Breast Ductal Carcinoma in Situ1 trial

Endometrial Cancer1 trial

Gastric Adenocarcinoma1 trial

Neoadjuvant1 trial

Brain Cancer1 trial

Locally Advanced1 trial

Urothelial Carcinoma1 trial

Real-world Study1 trial

Urothelial Cancer1 trial

EGFR Mutation1 trial

Tics1 trial

First-line Treatment1 trial

Advanced Solid Tumors1 trial

Lung Cancer1 trial

Resistance1 trial

Capecitabine1 trial

HER2-Positive Solid Tumor1 trial

Safety and Efficacy1 trial

Advanced Cancer1 trial

Refractory to Standard Therapies1 trial

Gastroesophageal Junction1 trial

Chemotherapy1 trial

Unspecified3 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Key Publications[6]

Related News